Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

In a bid to expand its oncology pipeline, biopharmaceutical company Gilead Sciences Inc. (GILD - Analyst Report) inked a definitive agreement to buy a Canada-based drug development company, YM BioSciences Inc. for $2.95 per share. The all-cash deal, already cleared by the Board of Directors at YM BioSciences, is worth approximately $510 million.

The closure of the deal is dependant on the approval of the stockholders of YM BioSciences along with the satisfaction of certain other customary conditions. Gilead expects to close the acquisition in the first quarter of 2013. The offer price of $2.95 per share represents a premium of 81% over YM BioSciences’ closing price of $1.63 on December 11 2012.

As per the terms of the deal, each shareholder of YM BioSciences will be eligible to receive $2.95 for each share in cash. Moreover, holders of warrants and stock options will be eligible to receive the difference between the offer price of the deal and the exercise price of the warrant or stock option in cash.

On completion of the deal, Gilead’s oncology pipeline will be strengthened by the addition of CYT387, which is YM BioSciences’ lead candidate. CYT387 has completed phase I/II studies for the myelofibrosis indication. The candidate is expected to be moved into phase III studies for the same indication in the second half of 2013. Gilead intends to evaluate CYT387 in other oncology indications as well, once the candidate becomes part of its pipeline.

Currently, the lead oncology candidate at Gilead is idelalisib (formerly GS-1101). The candidate, added to Gilead’s pipeline through its 2011 acquisition of Calistoga Pharmaceuticals, is under development for the chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma indications. Another oncology candidate at Gilead is simtuzumab (formerly GS- 6624). The candidate, added to Gilead’s pipeline through its 2010 acquisition of Arresto Biosciences, is being evaluated in multiple oncology indications.

Our Recommendation

We currently have a long-term Neutral recommendation on Gilead. The stock carries a Zacks #3 Rank (Hold) in the short run. Another biopharmaceutical company, Questcor Pharmaceuticals, Inc. (QCOR - Analyst Report) carries a Zacks #2 Rank (Buy) in the short run.

We have a Neutral stance on YM BioSciences. The stock carries a Zacks #2 Rank (Buy) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%